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Abstract: Peroxisome proliferator-activated receptor γ (PPARγ) is a master regulator of adipose
tissue biology. In obesity, phosphorylation of PPARγ at Ser273 (pSer273) by cyclin-dependent kinase
5 (CDK5)/extracellular signal-regulated kinase (ERK) orchestrates diabetic gene reprogramming
via dysregulation of specific gene expression. Although many recent studies have focused on the
development of non-classical agonist drugs that inhibit the phosphorylation of PPARγ at Ser273,
the molecular mechanism of PPARγ dephosphorylation at Ser273 is not well characterized. Here,
we report that protein phosphatase Mg2+/Mn2+-dependent 1A (PPM1A) is a novel PPARγphosphatase
that directly dephosphorylates Ser273 and restores diabetic gene expression which is dysregulated
by pSer273. The expression of PPM1A significantly decreases in two models of insulin resistance:
diet-induced obese (DIO) mice and db/db mice, in which it negatively correlates with pSer273.
Transcriptomic analysis using microarray and genotype-tissue expression (GTEx) data in humans
shows positive correlations between PPM1A and most of the genes that are dysregulated by pSer273.
These findings suggest that PPM1A dephosphorylates PPARγ at Ser273 and represents a potential
target for the treatment of obesity-linked metabolic disorders.
Keywords: obesity; insulin sensitivity; PPM1A; PPARγ S273 phosphorylation; diabetic
gene reprogramming
1. Introduction
Obesity, defined as an accumulation of excess body fat, is closely associated with metabolic
diseases, such as dyslipidemia, type 2 diabetes, cardiovascular diseases, and certain types of cancer [1–4].
Adipose tissue plays a pivotal role in excess energy storage and is considered an important regulator
of glucose and lipid metabolism, mediated through the secretion of adipokines [5–7]. Obesity
is characterized by abnormal adipose tissue and the dysregulation of adipokine secretion [8–10].
For example, the expression of pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α)
and interleukin-1β (IL-1β), and chemokines, such as chemokine ligand 2 (CCL2), are higher in obese
adipose tissue, whereas the secretion of the insulin-sensitizing adipokines, adiponectin and adipsin,
are lower in those tissues [11–17]. These circulating adipokines specifically orchestrate systemic
metabolism by regulating metabolism in peripheral tissues, such as liver, muscle, and macrophages.
Thus, an understanding of adipose tissue biology is critical for the most effective treatment of obesity
and metabolic diseases.
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Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear receptor that is a
master regulator of adipose tissue [18–20]. Indeed, numerous studies show that PPARγ is both
necessary and sufficient for fat cell differentiation [21–23]. The transcriptional activity of PPARγ is
activated by its ligands, which include thiazolidinediones (TZDs) [24]. In addition to its ligands,
recent studies demonstrated that post-translational modifications (PTMs) of PPARγ, including
phosphorylation, small ubiquitin-like modifier (SUMO)-ylation, acetylation, and ubiquitination, are
major regulatory mechanisms of PPARγ activation and PPARγ-mediated gene transcription [18,25,26].
Of these, phosphorylation is thought to be a crucial regulator of the transcriptional regulatory
activity of PPARγ. Phosphorylation of PPARγ at Ser112 (pSer112) by mitogen-activated protein
kinases (MAPKs) suppresses its transcriptional activity, and therefore adipocyte differentiation [27].
Recently, we demonstrated that PPARγ is phosphorylated at Ser273 by cyclin-dependent kinase
5 (CDK5)/extracellular signal-regulated kinase (ERK), and this phosphorylation does not affect its
adipogenic activity but instead dysregulates a specific set of genes, the expression of which is altered
in obesity and/or type 2 diabetes [28,29].
Although the phosphorylations of PPARγ are known to be performed by CDK5 and MAPKs,
little is known about the intrinsic negative regulators of such phosphorylations. It was reported that
protein phosphatase 5 specifically dephosphorylates PPARγ and glucocorticoid receptor (GR) [30].
In addition, protein phosphatase Mg2+/Mn2+-dependent 1B (PPM1B), and protein phosphatase 2C
delta (WIP1), which are serine/threonine phosphatases belonging to the protein phosphatase Mg2+/Mn2
(PPM) family, dephosphorylate PPARγ at Ser112, which activates its transcriptional activity, thereby
increasing adipogenesis and fat accumulation in vitro and in vivo [31,32]. However, the phosphatases
responsible for the dephosphorylation of PPARγ at Ser273 are still unknown. Since it was shown that
the members of PPM family phosphatase function as a PPARγ phosphatase [31,32], we hypothesized
that PPM family phosphatases could dephosphorylate PPARγ at Ser273, and we interrogated seven
members of the PPM family using a PPARγ dephosphorylation assay. Among them, we identified
a novel protein phosphatase Mg2+/Mn2+-dependent 1A (PPM1A), which specifically and directly
dephosphorylates PPARγ at Ser273.
It was reported that the activation of PPM1A requires magnesium and/or manganese
ions [33,34]. PPM1A specifically binds to its substrates and catalyzes the dephosphorylation of
these substrates [35,36]. For example, p38 MAPK, small mothers against decapentaplegic homolog
2 (SMAD2) and SMAD3, MAPK kinase 4 (MKK4), and MKK6 are reported as specific substrates of
PPM1A, and this direct interaction is involved in the regulation of diverse cellular processes, including
apoptosis, the cell cycle, and differentiation [37,38]. In this study, we show that PPM1A-mediated
dephosphorylation of PPARγ at Ser273 in mature adipocytes restores the expression of most of the
genes that are dysregulated by pSer273. These data strongly suggest that PPM1A plays an important
role in the regulation of the diabetic gene reprogramming by dephosphorylating PPARγ at Ser273,
and that PPM1A may represent a therapeutic target for obesity and type 2 diabetes.
2. Materials and Methods
2.1. Cell Culture
3T3-L1, human embryonic kidney 293 (HEK-293) cells were purchased from American Type
Culture Collection (ATCC, Manassas, VA, USA) and cultured in Dulbecco’s modified Eagle’s medium
(DMEM) containing 10% fetal bovine serum (Gemini Bio-products, West Sacramento, CA, USA) and
1% penicillin/streptomycin (Thermo Fisher Scientific, Waltham, MA, USA) at 37 ◦C under 5% CO2
conditions. Adipocyte differentiation was performed by a previously described procedure [28]. Briefly,
3T3-L1 pre-adipocytes were cultured with DMEM containing 10% fetal bovine serum (FBS) until they
reached 100% confluence. After 2 days, the maintaining media was changed by differentiation media
containing 3-isobutyl-1-methylxanthine (IBMX, 0.5 mM), dexamethasone (1 µM), and insulin (850 nM).
Then, the media was changed by differentiation media containing insulin (850 nM) once every 2 days.
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All experiments performed 7 days after changing the differentiation media. All chemicals used for cell
culture were purchased from Sigma-Aldrich (St. Louis, MO, USA).
2.2. Expression Plasmids and RNA Interference
Expression plasmids for FLAG epitope-tagged wild-type (WT) and PPARγS273A were
used as described previously [28]. WT human PPM1A, 1B, 1D, 1F, 1J, 1K, and 1M were
obtained from Korea Research Institute of Bioscience and Biotechnology (KRIBB). PPM1A,
R174G, or D239N substitutions were constructed using QuickChange II Site-Directed Mutagenesis
Kit obtained from Agilent Technologies (Santa Clara, CA, USA). All mammalian expression
plasmids were transfected using LipofectamineTM 2000 transfection reagent (ThermoFisher Scientific,
Waltham, MA, USA) following the manufacturer’s instructions. siRNAs for mouse PPM1A #1
(5′-CCAAGTGGACTTGAG-ACATGGTCAT-3′) and #2 (5′-GACATGGTCATTCTTTGCTGTATAT-3′)
were purchased from Shanghai GenePharma (Shanghai, China). 3T3-L1 cells were transfected with
siRNAs using LipofectamineTM RNAiMax transfection reagent (ThermoFisher Scientific, Waltham,
MA, USA).
2.3. Lentivirus Production and Infection
Murine PPM1A WT, R174G, and D239N were sub-cloned into pLenti-GIII-CMV-GFP-2A-Puro
(Applied Biological Materials, Richmond, BC, Canada). For lentiviral package plasmids, we used
pMDLg/pRRE and pRSV/REV, while pLV-VSVG was used as an envelope plasmid (Addgene, #12251,
#12253, #82724). HEK-293T cells were transfected with each lentiviral vector, packaging plasmids,
and envelope plasmid under 5:2:2:1 ratio. Produced lentivirus from media were infected into 3T3-L1
adipocytes with polybrene (Sigma-Aldrich, St. Louis, MO, USA).
2.4. Immunoprecipitation and Immunoblotting
HEK-293 cells expressing PPARγ were treated with 500 nM of phorbol 12-myristate 13-acetate
(PMA), and total cell lysates were incubated with FLAG M2 agarose (Sigma-Aldrich, St. Louis, MO,
USA) at 4 ◦C. Immunoprecipitates, total cell, or tissue lysates were analyzed with phospho-specific
antibody against PPARγ at Ser273 [28], anti-PPARγ at Ser112 (Biocompare, San Francisco, CA, USA),
or anti-PPARγ antibody (Santa Cruz Biotechnology, Dallas, TX, USA). The antibodies used in this
study including anti-glutathione S-transferase (GST), aP2, and C/EBPα were purchased from Santa
Cruz Biotechnology (Dallas, TX, USA), while anti-HA, p-ERK1/2, ERK, adiponectin, β-tubulin, Histone
2A, and HSP90 were purchased from Cell Signaling Technology (Danvers, MA, USA).
2.5. In Vitro Phosphatase Assay
PPM1A human recombinant and active ERK1 were purchased from Prospec (Ness-Ziona, Israel)
and SignalChem (Richmond, British Columbia, Canada), respectively. Glutathione S-transferase
(GST)-fused PPARγ was incubated with active ERK1 in kinase assay buffer (25 mmol/L Tris-HCl, pH 7.5,
5 mmol/L β-glycerophosphate, 2 mmol/L DTT, 0.1mmol/L Na3VO4, 10 mmol/L MgCl2) containing 20
µmol/L ATP for 20 min at 30 ◦C. Then, purified phosphorylated GST-fused PPARγ was added into
PPM1A human recombinant containing PPM1A phosphatase buffer [38] and incubated 30 min at 30 ◦C.
To check the effect of catalytic inactive mutants of PPM1A (R174G and D239N) in dephosphorylation
of PPARγ, HEK-293 cells were transfected with mutants expressing vector. Immunopurified PPM1As
were incubated with phosphorylated GST-fused PPARγ in PPM1A phosphatase buffer for 30 min at
30 ◦C. All reactions were terminated by the addition of protein sample buffer. Phosphorylation of
PPARγ was analyzed by SDS-PAGE with phospho-specific antibody against PPARγ at Ser273, anti-GST,
or PPM1A antibodies.
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2.6. Dot Blot Assay
PPM1A human recombinant was incubated with phospho-Ser273 peptide, which conserves
the amino acid sequence of PPARγ (TGKTTDK-pS-PFVIYDM, New England peptide, Gardner, MA,
USA) in PPM1A phosphatase assay buffer for 20 min at 30 ◦C. A portion was dotted on nitrocellulose
membrane and dried for 3 h at real-time (RT). After dry step, the membrane was washed by Tris-buffered
saline and Tween 20 (TBST) 3 times per 10 min. Washed membrane was blocked by 5% bovine serum
albumin (BSA) dissolved in TBST and immunoblotting was performed with phospho-specific antibody
against PPARγ at Ser273 as described previously.
2.7. Subcellular Fractionation
Fully differentiated 3T3-L1 cells were washed by ice-cold PBS buffer, and the centrifuged pellet
was resuspended with 20 mM hydroxyethyl piperazine ethane sulfonicacid (HEPES) pH 7.4. Using
a 1 mL syringe, cells were lysed 10 times by needle suspension. After incubating for 20 min on ice,
lysates were fractionated into nuclei in pellet and cytoplasm in supernatant by 720× g centrifugation
for 5 min at 4 ◦C. Then the pellet was resuspended with 5 mM HEPES pH 7.9 added with 400 mM
NaCl and needle suspension was performed 20 times. After 30 min on ice, nuclear proteins acquired
by centrifugation at 24,000× g for 30 min at 4 ◦C. Cytoplasmic and nuclear proteins were quantified by
Bradford assay and proteins were detected by Western blotting.
2.8. In Vitro Insulin-Resistance (IR) Model
For an experimental procedure of IR-induced model in vitro, we followed Lo. et. al. [39]. Briefly,
fully differentiated 3T3-L1 cells were washed by PBS buffer, and changed to low-glucose (1 g/L) DMEM
containing 0.5% BSA and 2.5 nM of TNF-α, without serum. After 24 h, total RNAs were isolated.
2.9. Real-Time RT-PCR (Quantitative PCR, qPCR)
Total RNAs were isolated using TRIzol reagent purchased from Thermo Fisher Scientific (Waltham,
MA, USA). Reverse-transcription of the RNA was performed with ABI Reverse Transcription Kit.
qPCR was performed using 7900HT Fast Real-Time PCR System (Life Technologies, Carlsbad, CA,
USA) following the manufacturer’s instructions. Relative mRNA expression levels of each gene were
normalized to 36B4 or TATA-binding protein TBP. Each analysis was conducted in triplicates. Data
were analyzed by Microsoft Excel (Microsoft, Redmond, WA, USA).
2.10. Correlation Analysis in Human Adipose Tissues
To analyze the correlation between PPM1A and PPARγphosphorylation at Ser273 in lean and obese
humans, GSE55200, from public Gene Expression Omnibus (GEO) database accessible at the National
Center for Biotechnology Information (NCBI, Bethesda, MD, USA), was analyzed. We analyzed the
expression levels of PPM1A and genes responsive to PPARγ phosphorylation at Ser273 as described
previously in human subcutaneous adipose tissue [40,41].
2.11. Animals
All animal experiments were performed according to procedures approved by the Ulsan National
Institute of Science and Technology’s Institutional Animal Care and Use Committee. Five-week-old
male C57BL/6J mice (DBL, Chungbuk, Korea) were fed a high-fat diet (60% kcal fat, D12492, Research
Diets Inc., New Brunswick, NJ, USA) for 8 weeks. The db/db mice used in this study were purchased
from the Jackson Laboratory (Bar Harbor, ME, USA).
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3. Results
3.1. PPM1A is a Phosphatase that Acts on PPARγ
Recent studies showed that members of the PPM family could be the serine phosphatases of
PPARγ [31,32]. Therefore, we aimed to identify the phosphatase for the Ser273 residue of PPARγ
by interrogating a number of PPMs. Of the seven tested, we found that both PPM1A and PPM1B
specifically dephosphorylated PPARγ at Ser273 after phorbol myristate acetate (PMA) treatment,
and that PPM1A did so more effectively than PPM1B (Figure 1A). Consistent with previous reports,
PPM1B dephosphorylates PPARγ at Ser112 [31], but interestingly, PPM1A also inhibits PMA-mediated
PPARγ phosphorylation at Ser112. To further investigate the effects of PPM1A on the phosphorylation
of PPARγ, we overexpressed PPM1A in HEK-293 cells and found that the degree of dephosphorylation
of PPARγ by PPM1A is proportional to the level of PPM1A expression (Figure 1B). It was reported that
the phosphorylation of PPARγ at Ser273 is mediated by ERK [29]. Therefore, we tested whether the
dephosphorylation by PPM1A might be the result of an inhibition of ERK activation following PMA
treatment. However, forced expression of PPM1A did not change the degree of PMA-induced ERK
phosphorylation, suggesting that the dephosphorylation of PPARγ by PPM1A is not caused by the
indirect inhibition of ERK.
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Figure 1. Identification of novel phosphatase of peroxisome proliferator-activated receptor (PPARγ) at
Ser273 and Ser112. (A) Human embryonic kidney 293 (HEK-293) cells were transfected with protein
phosphatase Mg2+/Mn2 (PPM) and PPARγ. PPARγ was phosphorylated by phorbol myristate acetate
(PMA) (500 nM) for 30 min. Immunoprecipitated PPARγ were analyzed by Western blotting. (B)
HEK-293 cells were transfected with protein phosphatase Mg2+/Mn2+-dependent 1A (PPM1A) with
PPARγ in a dose-dependent manner. PPARγ phosphorylation was analyzed in immunoprecipitated
cell lysates, and PPM1A, extracellular signal-regulated kinase (ERK)1/2, and ERK1/2 phosphorylation
were measured in whole cell lysate (input) by Western blotting. (C) Wild-type (WT) PPM1A and its
catalytically inactive mutants (R174G and D239N) were transfected into HEK-293 cells with PPARγ.
PPARγ phosphorylation was analyzed by Western blotting. HSP90 was used as loading control.
To determine whether PPM1A phosphatase activity is required for PPARγ dephosphorylation,
we generated two catalytically inactive PPM1A mutants, R174G and D239N [34], and found that both
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lost their ability to dephosphorylate PPARγ at Ser112 and Ser273, while not affecting PMA-induced
ERK activation (Figure 1C). Taken together, these results strongly suggest that PPM1A is a specific
phosphatase of PPARγ at both Ser112 and Ser273 in the cell culture system.
3.2. PPM1A Directly Dephosphorylates PPARγ at Ser273 but not Ser112
We next determined the effect of PPM1A on PPARγ dephosphorylation in a cell-free system.
After purifying a glutathione S-transferase (GST)-PPARγ recombinant fusion protein, we directly
phosphorylated PPARγ at Ser273 using active ERK. Then, we performed an in vitro phosphatase assay
using recombinant active PPM1A. As shown in Figure 2A, PPM1A directly dephosphorylated PPARγ
at Ser273 but not at Ser112. These results indicate that PPM1A is a direct phosphatase of PPARγ at
Ser273, and that the dephosphorylation by PPM1A at Ser112 in cells is indirect. Furthermore, when
we incubated a phosphopeptide including the pSer273 residue with active PPM1A, phosphorylation
at Ser273 significantly decreased (Figure 2B). Due to PPM1A [33,34], we further tested the effect
of both ions on dephosphorylating PPARγ at Ser273. As shown in Figure 2C,D, the phosphatase
activity of PPM1A against pSer273 is much higher in the presence of both Mg2+ and Mn2+ ions,
but pSer112 is unchanged. Next, to determine whether the catalytic activity of PPM1A is required for
the dephosphorylation of PPARγ, we immunopurified wild-type (WT) PPM1A and the two catalytic
inactive mutants of PPM1A from HEK-293 cells. After phosphorylating PPARγ at Ser273, we incubated
phosphorylated PPARγ with PPM1As. WT PPM1A, but not the two catalytically inactive mutants,
dephosphorylated PPARγ (Figure 2E). Taken together, these results strongly suggest that PPM1A is a
specific and direct phosphatase of PPARγ at Ser273, but not Ser112.
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Figure 2. PPM1A directly dephosphorylates PPARγ at Ser273. (A) In vitro PPM1A phosphatase assay
was performed with full-length glutathion S-transferase (GST -fused phosphorylated PPARγ and
recombinant PPM1A. Total PPARγ and PPARγ phosphorylation were analyzed by Western blotting.
(B) Dot blot assay was performed using phospho-peptide flanking pSer273 residue with recombinant
PPM1A. S273 phosphorylation of PPARγ was analyzed by Western blotting. Three independent
experiments were performed and the level of PPARγ phosphorylation was quantified by Image Studio.
(C,D) In vitro PPM1A phosphatase assay was performed in the presence of magnesium and manganese
ions (20 mM and 5 mM, respectively). Western blots were performed to detect each protein indicated.
(E) In vitro PPM1A phosphatase assay was performed with GST-fused phosphorylated PPARγ and
immune-purified WT PPM1A and two utants. PPARγ phosphorylation as analyzed by Western
blotting. *** p < 0.001; Error bars indicat sta dard error of the mean (SEM).
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3.3. PPM1A Physically Interacts with PPARγ
Since PPM1A directly dephosphorylates PPARγ, it is expected that they would be localized
to the nucleus. Thus, we analyzed the subcellular localization of both PPM1A and PPARγ and
found that both were predominantly localized in the nucleus (Figure 3A). Next, we performed
co-immunoprecipitation experiments to determine whether PPM1A binds to PPARγ. Endogenous
PPM1A specifically interacts with endogenous PPARγ in adipocytes and vice versa (Figure 3B,C).
In addition, PPM1A specifically interacts with PPARγ when co-expressed in HEK-293 cells (Figure 3D).
Interestingly, a phosphorylation-defective mutant of PPARγ (S273A) interacts normally with PPM1A.
Furthermore, PMA does not affect the interaction between PPM1A and PPARγ, suggesting that the
phosphorylation status of PPARγ is not critical for its interaction with PPM1A. The catalytically
inactive PPM1A mutant (R174G) retains its ability to interact with PPARγ, but the D239N mutation
significantly reduces the interaction (Figure 3F). These results are consistent with previous reports
that Asp239 residue is critical for substrate binding by coordinating to metal M2 and bridging with
metal-bound water [42]. Together, these results indicate that PPM1A physically interacts with PPARγ
in a phosphorylation-independent manner.
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Figure 3. PPM1A directly interacts with PPARγ in adipocyte. (A) Western blot analysis of subcellular
fractions in 3T3-L1 adipocytes. Histone H2A and β-tubulin was detected for nucleus and cytoplasmic
marker protein, respectively. (B, C) Endogenous PPM1A and PPARγ were immunoprecipitated and
physical interaction between them was analyzed by Western blotting. (D–F) PPARγwas phosphorylated
by PMA (500 nM) for 30 min in HEK-293 cells. (D) HEK-293 cells were transfected with PPARγ and
PPM1A. Immunoprecipitation was performed, and each protein was analyzed by Western blotting. (E)
WT PPARγ and phospho-defective mutant of PPARγ (S273A) were transfected in HEK-293 cells with
PPM1A. Immunoprecipitation was performed, and each protein was analyzed by Western blotting. (F)
WT PPM1A and its catalytically inactive mutants R174G and D239N were transfected in HEK-293 cells
with PPARγ. Immunoprecipitation was performed and each protein was analyzed by Western blotting.
3.4. PPM1A Specifically Regulates the Expression of a Diabetic Gene Set that is Dysregulated by pSer273
To elucidate the functional roles of PPM1A on pSer273, we investigated the effect of PPM1A on
pSer273-mediated gene regulation in adipocytes. Specific siRNAs targeting PPM1A were introduced
into adipocytes, which dramatically reduce the expression of PPM1A (Figure 4A). The expression of
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PPARγ is not changed by PPM1A knockdown (Figure 4B). Importantly, most of the genes known
to be specifically dysregulated by pSer273 are sensitive to the knockdown of PPM1A (Figure 4C).
These include adiponectin and adipsin, which are adipokines that are important regulators of insulin
sensitivity and glucose homeostasis [14–17].
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Figure 4. Knockdown of PPM1A downregulates gene sets dysregulated by pSer273. 3T3-L1 adipocytes
were transfected with specific human siRNAs targeting PPM1A. (A) Western blot of 3T3-L1 cell lysates
transfected by siRNAs. (B, C) 3T3-L1 cells were introduced with specific mouse PPM1A targeting
siRNAs. Relative mRNA expression of PPM1A and PPARγ are shown in (B), and expression of specific
gene sets dysregulated by pS273 are shown in (C). * p < 0.05; ** p < 0.01; Error bars indicate SEM; n.s.,
not significant.
In contrast, the forced expression of PPM1A in adipocytes has opposite effects to the knockdown
of PPM1A with gene regulation. The lentiviral overexpression of WT PPM1A and two catalytic inactive
mutants does not change the expression of PPARγ in adipocytes (Figure 5A,B). However, WT PPM1A
markedly increases the expression of most of the specific gene set that is dysregulated by pSer273,
but the R174G and D239N mutants do not (Figure 5C). Taken together, these results strongly suggest
that PPM1A regulates the diabetic gene program by dephosphorylating PPARγ at Ser273.
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3.5. Knockdown of PPM1A Devastates Insulin Resistant Status in Adipocytes
Next, we aimed to determine the physiological relevance of PPM1A in adipocyte biology. Western
blotting and real-time PCR analysis revealed that PPM1A is expressed in pre-adipocytes, and that
its expression significantly increases during adipogenesis (Figure 6A). In addition, the expression
of PPARγ and adipogenic marker genes, including aP2, C/EBPα, and adiponectin, also significantly
increases (Figure 6B), indicating that PPM1A might have important roles in differentiated adipocytes.
It is well characterized that pS273 is linked to obesity and insulin resistance [28,29] and blocking
pSer273 by specific PPARγ ligands shows improved insulin sensitivity [43–45].
Thus, we tried to determine whether PPM1A has a potential role in insulin sensitivity. It was
shown that insulin resistance can be modeled by treating fully differentiated adipocytes with TNF-α [39].
Therefore, we treated adipocytes with TNF-α, which dramatically increased the expression of genes
involved in insulin resistance in adipocytes, such as IL-6, CCL2, and chemokine ligand 9 (CCL9), but
significantly reduced glucose transporter 4 (GLUT4) expression (Figure 6C). Interestingly, the expression
of PPM1A was significantly decreased in this model, and those genes were dramatically altered by
PPM1A knockdown in adipocytes. The expression of IL-6, CCL2, and CCL9 dramatically increases
by specific knockdown of PPM1A and the expression of GLUT4 is significantly decreased by PPM1A
knockdown. These results strongly suggest that PPM1A is positively associated with insulin sensitivity
in adipocytes.
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Figure 6. P M1A ameliorates insulin resistance in adipocytes. (A) Western blot of P M1A and
adipogenic marker proteins from 3T3-L1 cells during adipogenesis. (B) Relative mRNA expression of
PPM1A and adipogenic marker genes were investigated by RT-qPCR (n = 3). (C) Control and PPM1A
siRNAs introducing 3T3-L1 adipocytes were treated with tumor necrosis factor-α (TNF-α) for 24 h and
mRNA expression of PPM1A, insulin resistance marker genes (IL6, CCL2, CCL9), and insulin sensitivity
marker gene (GLUT4) was measured by RT-qPCR. * p < 0.05; ** p < 0.01; *** p < 0.001 vs. ‘siCtrl/NT’;
# p < 0.05; ### p < 0.001 vs. ‘siCtrl/TNF-α’; Error bars indicate SEM.
3.6. PPM1A is Negatively Correlated with pSer273
We en investigated the physiological relevance of PPM1A in adipos tissue. First, we used
two different models: high-fat iet (HFD)- nduced obese mice and genetically obesity mice (db/db).
As show in Figure 7A,B, the phosphorylation of PPARγ at Ser273 is very high in the adipos of these
mice, as previously reported [28]. Interestingly, PPM1A expression was significantly lower in the
adipose ssue of both HFD-fed and db/db mice tha in control mice, indicating that there is a negativ
association be ween PPM1A expression and pSer273 (Figure 7C,D). To furthe evaluate this correlatio ,
we interrogated a public GSE55200 database whi h c mpares gene expression in lean and obese human
subcutaneous adipose tissue (Table 1). The expression of PPM1A is significantly lower in obese than
in norma adipose. By contra t, the expression of pr -inflammatory cytokines, such as TNF-α and
CCL2, is much higher. Furthermore, the expression of adiponectin and GLUT4 is significantly lower.
In addition, most of th genes dysregulated by pSer273 are significantly increased in obese adipose
tissue (Table 1). To further check the correlation between PPM1A expression and phosphorylation
of PPARγ at Ser273, we analyzed the relative expression of PPM1A and pSer273 specific genes in
human subcutaneous adipose tissue using GTEx database (Figure 7E). Indeed, the expression of most
of the genes dysregulated by pSer273 positively correlated with the expression of PPM1A. Taken
together, our results strongly suggest that PPM1A is negatively correlated with pSer273 in both mice
and humans.
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Figure 7. Negative correlation between PPM1A and the phosphorylation of PPARγ at Ser273 in
pathophysiological conditions both in mice and humans. (A) Western blot analysis of PPM1A, PPARγ,
and PPARγ phosphorylation at Ser273 in adipose tissue of both normal chow diet (NCD)-fed mice
and high-fat diet (HFD)-fed mice for 8 weeks. The expression of PPM1A and the phosphorylation of
PPARγ at Ser273 are normalized by HSP90 and total PPARγ, respectively (shown as bar graphs). (B)
Relative mRNA expression of PPM1A in adipose tissue in the same mice (n=3). (C) Western blot of
PPM1A, PPARγ, and PPARγ phosphorylation at Ser273 in adipose tissue of 10 week-old C57BL6/J and
db/db mice. The expression of PPM1A and the phosphorylation of PPARγ at Ser273 are normalized by
HSP90 and total PPARγ, respectively (shown as bar graphs). (D) Relative mRNA expression of PPM1A
in adipose tissue in the same mice (n = 3). (E) Pearson correlation coefficient between PPM1A and
gene set responsive to pSer273 within human subcutaneous adipose tissue is calculated. * p < 0.05;
** p < 0.01; *** p < 0.001; **** p< 0.0001; Error bars indicate SEM.
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Table 1. Differential gene expression in subcutaneous adipose tissue of unhealthy obese individuals.
Affymetrix ID Gene Symbol Gene Name log2 FC(vs. Lean Healthy) p-Value
16784909 Ppm1a Protein phosphatase,Mg2+/Mn2+ dependent, 1A –0.02583 0.004725 **
17117110 Cd24a CD24 molecule, type A –0.03623 0.291983
16669796 Txnip Thioredoxin interactingprotein –0.02935 0.005334 **
16844294 Nr1d1 Nuclear receptor subfamily 1group D member 1 0.054739 0.042975 *
16733435 Aplp2 Amyloid beta precursor likeprotein 2 0.012981 0.048507 *
17048563 Peg10 Paternally expressed 10 0.158202 0.018165 *
16852660 Acyl ATP citrate lyase −0.10524 0.037731 *
16950609 Cidec Cell death inducing DFFAlike effector C −0.04005 0.000383 ***
17001100 Nr3c1 Nuclear receptor subfamily3 group C member 1 −0.07386 0.000149 ***
17064251 Rarres2 Retinoic acid receptorresponder 2 −0.08898 0.011576 *
17070441 Car3 Carbonic anhydrase 3 −0.394 0.001141 **
16693082 Selenbp1 Selenium binding protein 1 −0.04191 0.034659 *
16938378 Nr1d2 Nuclear receptor subfamily 1group D member 2 −0.02497 0.070348
16935042 Ddx17 DEAD-box helicase 17 −0.00854 0.177737
16956244 Rybp RING1 And YY1 bindingprotein 0.002819 0.427001
16949397 Adipoq Adiponectin, C1Q anndcollagen domain containing −0.02938 0.000331 ***
16856299 Cfd Complement factor D,adipsin 0.00749 0.227859
16830343 Slc2a4 Solute carrier family 2member 4, GLUT4 −0.46174 1.4 × 10−7 ***
17001763 Tnf Tumor necrosis factor 0.055804 2.1 × 10−5 ****
16833204 Ccl2 C-C motif chemokine ligand2 0.364464
4.52 × 10−5
****
Expression of PPM1A, pSer273 responsive genes (Cd24a, Txnip, Nr1d1, Aplp2, Peg10, Acyl, Cidec, Nr3c1, Rarres2,
Car3, Selenbp1, Nr1d2, Ddx17, Rybp, Adiponectin, and Adipsin), insulin sensitivity-related genes (Glut4), and insulin
resistance-related genes (Tnf, Ccl2) in human adipose tissue is analyzed (GSE55200). Log fold changes (log2FC) of
unhealthy obese individuals (n = 8) versus lean healthy individuals (n = 7) are calculated. * p < 0.05; ** p < 0.01; *** p
< 0.001; **** p < 0.0001.
4. Discussion
Post-translational modifications of PPARγ orchestrate various functions of the protein [18,25,26].
In obesity, phosphorylation of PPARγ on the Ser273 residue by CDK5 leads to dysregulation of a specific
gene set [28]. In addition to the effect of CDK5 on Ser273, ERK is shown to regulate the diabetogenic
effect of PPARγ [29]. These studies collectively suggest that pSer273 is a potential therapeutic target for
metabolic diseases. In this study, we demonstrate that PPM1A is a novel protein phosphatase of PPARγ
that directly dephosphorylates pSer273, reprogramming anti-diabetic gene expression (Figure 8). First,
PPM1A interacts with PPARγ and directly dephosphorylates at Ser273. Second, genetically altered
expression of PPM1A significantly affects the expression of the gene set that is dysregulated by pSer273
in adipocytes. Third, PPM1A expression negatively correlates with the degree of phosphorylation
of PPARγ, both in obese mice and human adipose tissue. Finally, transcriptomic analyses are highly
consistent with this relationship.
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Figure 8. Schematic model of dephosphorylation of PPARγ at Ser273 by PPM1A. In normal status
(insulin sensitive condition), a degree of PPARγ phosphorylation at Ser273 is reduced by the action
of PPM1A in adipocytes. Dephosphorylated PPARγ orchestrates the specific target gene expression
including insulin-sensitizing adipokines, such as adiponectin and adipsin. In obese status (insulin
resistant condition), however, phosphorylation of PPARγ at Ser273 significantly increases because of the
lower level of PPM1A expression. Phosphorylated PPARγ dysregulates the diabetic gene programming
so that adipocytes change into insulin resistance phenotype.
Although a number of studies identified phosphatases of PPARγ, most focused on pSer112.
Our results show that PPM1A reduces the level of phosphorylation at Ser112, but an in vitro
phosphatase assay indicates that this dephosphorylation is not direct. The Ser112 residue of PPARγ is
phosphorylated by ERK and c-Jun N-terminal kinase (JNK), but not p38 MAPK, and reduces PPARγ
activity. Paradoxically, the same site can be phosphorylated by CDK7 and CDK9, which increases the
activity of PPARγ [46,47]. We showed that there is no effect of PPM1A on the phosphorylation of ERK
in cells (Figure 1), but the exact mechanism whereby PPM1A reduces pSer112 in adipocytes remains to
be elucidated. Further mechanistic studies should be conducted to confirm the direct target of PPM1A
that affects phosphorylation at Ser112.
Recent studies have shown that PPM1A plays an important role in metabolism [37,48–50].
Unhealthy adipocytes are exposed to adipose tissue-resident macrophages, which are phenotypically
defined as M1 macrophages [2,51–54]. Pro-inflammatory cytokines, including IL-1β, IL6, and TNF-α,
secreted by M1-polarized macrophages, alter the metabolic phenotype of adipose tissue [55–58]. Smith
et al. showed that PPM1A regulates monocyte–macrophage differentiation, reduces the expression of M1
macrophage marker genes, and inhibits the production of pro-inflammatory cytokines [59]. In addition,
PPM1A terminates TNF-α-induced inhibitor κB kinase beta (IKKβ) activation and transforming growth
factor beta (TGFβ) signaling by dephosphorylating IKKβ and SMAD2/3, respectively [38,60]. These
results suggest that PPM1A plays an important role in inhibiting pro-inflammatory cytokine-induced
inflammatory signaling. Interestingly, our previous studies demonstrated that dephosphorylation of
PPARγ at Ser273 is responsible for anti-inflammatory functions by controlling macrophage polarization
which decreased M1 polarization, but increased M2 phenotypes [44,45]. Furthermore, we found
that TNF-α-induced phosphorylation of PPARγ at Ser273 increased pro-inflammatory response in
adipocytes [45]. Notably, insulin-resistant TNF-α-treated differentiated 3T3-L1 adipocytes show
significantly lower PPM1A expression. Specifically, PPM1A recovers insulin sensitivity-related
gene expression which is dysregulated by TNF-α (Figure 6) and upregulates the expression of
insulin-sensitizing adipokines, adiponectin, and adipsin (Figures 4 and 5). Together, we highlight that
PPM1A may represent a therapeutic target for metabolic diseases in many aspects, such as increasing
anti-inflammatory responses and enhancing the secretion of insulin-sensitizing adipokines which
depends on dephosphorylation of PPARγ at Ser273.
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Both extracellular and intracellular magnesium deficits are frequently detected in patients with
type 2 diabetes and in overweight or obese children [61,62]. Low Mg2+ concentrations are closely
associated with post-receptor impairment in the insulin signaling pathway [61,63,64]. In addition,
a series of recent studies revealed lower concentrations of Mg2+ in the liver, small intestine, and bone
of lean mice compared with obese mice [65–67]. Furthermore, epidemiological studies conducted
worldwide suggest that a higher intake of Mn2+ is associated with a lower risk of obesity [61,68,69].
Thus, the Mg2+/Mn2+-dependency of PPM1A for the dephosphorylation of PPARγ is an important
consideration when evaluating the phosphatase as a therapeutic target. However, the intracellular
concentrations of Mg2+ and Mn2+ are strictly regulated, and failure of homeostasis is involved in
several diseases [70,71]. For example, hypermagnesemia is common in renal failure patients [72],
and an accumulation of manganese in the brain can cause neurodegenerative disorders [73]. Thus,
further studies are required to uncover the molecular mechanisms which promote the expression
of PPM1A and to develop the specific activators of PPM1A rather than regulating the intracellular
concentrations of Mg2+ and Mn2+.
Our data suggest the critical roles for PPM1A as a novel phosphatase of PPARγ, which finely
orchestrates diabetic gene expression in adipocytes. Although further studies are required to elucidate
the relationship between PPM1A and metabolic diseases, our study proposes that PPM1A may
represent a promising therapeutic target for obesity and metabolic disorders.
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